Key result
Heart failure is associated with increased platelet activation and hypercoagulability, including elevated beta-thromboglobulin, fibrinopeptide A, and D-dimer.
Heart failure is associated with platelet activation and hypercoagulability, providing a pathophysiological rationale for investigating antiplatelet or anticoagulant therapies in this population.
Answers are grounded in this paper and cite their sources.
Increased platelet activation markers in heart failure; leaves open whether targeted antithrombotic therapy improves outcomes.
Thromboembolism is an important complication in patients with heart failure. A variety of factors associated with heart failure predispose to thrombosis. These include vascular pathology, increased coagulability, and impaired flow. The focus of this review is to summarize data on platelet function and coagulation indices in heart failure. Several studies have shown that patients with heart failure have increased plasma concentrations of beta-thromboglobulin, a marker of platelet activation. Increased plasma concentrations of fibrinopeptide A and thrombin activation have also been demonstrated. In addition, plasma concentrations of endothelial procoagulants, von Willebrand factor, fibrinolytic products, and D-dimer are also increased during heart failure. If platelet activation and hypercoagulability are a surrogate for clinical events, treatment with antiplatelet or anticoagulant therapy can potentially reduce thromboembolism and mortality in heart failure.
No takes yet. Share an insight, caveat, or question.
Syed M. Jafri (1997) conducted a review in Heart failure. Heart failure was evaluated. Heart failure is associated with increased platelet activation and hypercoagulability, including elevated beta-thromboglobulin, fibrinopeptide A, and D-dimer.
Synapse has enriched 10 related papers. Consider them for comparative context: